Effects of bupropion on the reinstatement of nicotine-induced conditioned place preference by drug priming in rats

Pharmacological Reports

Volumn 63, Issue 2, 2011, Pages 362-371

  Budzyńska, Barbara ^a   Biała, Grazyna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Bupropion; Morphine; Nicotine; Place conditioning; Rats; Reinstatement

Indexed keywords

AMFEBUTAMONE; MORPHINE; NICOTINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; LOCOMOTION; MALE; NONHUMAN; PLACE PREFERENCE; RAT; RELAPSE; TOBACCO DEPENDENCE; TREATMENT OUTCOME;

EID: 79955931971     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70502-3     Document Type: Article

References (51)

1. Araki H, Kawakami KY, Jin C, Suemaru K, Kitamura Y, Nagata M, Futagami K et al.: Nicotine attenuates place aversion induced by naloxone in single-dose, morphine-treated rats. Psychopharmacology (Berl), 2004, 171, 398-404. (Pubitemid 38200051)
2. Biala G, Budzynska B: Calcium-dependent mechanisms of the reinstatement of nicotine-conditioned place preference by drug priming in rats. Pharmacol Biochem Behav, 2008, 89, 116-125.
3. Biala G, Budzynska B: Reinstatement of nicotine-conditioned place preference by drug priming: effects of calcium channel antagonists. Eur J Pharmacol, 2006, 537, 85-93.
4. Biała G: Calcium channel antagonists suppress nicotine-induced place preference and locomotor sensitization in rodents. Pol J Pharmacol, 2003, 55, 327-335.
5. Biała G, Kruk M: Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep, 2009, 61, 236-244.
6. Biała G, Weglińska B: On the mechanism of crosstolerance between morphine- and nicotine-induced anti-nociception: Involvement of calcium channels. Prog Neuropsychopharmacol Biol Psychiatry, 2006, 30, 15-21.
7. Calcagnetti DJ, Schechter MD: Nicotine place preference using the biased method of conditioning. Prog Neuropsychopharmacol Biol Psychiatry, 1994, 18, 925-933. (Pubitemid 24234875)
8. Carr KD: Augmentation of drug reward by chronic food restriction: behavioral evidence and underlying mechanisms. Physiol Behav, 2002, 76, 353-364.
9. Corrigall WA, Franklin KB, Coen KM, Clarke PB: The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology, 1992, 107, 285-289.
10. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A: Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl), 2003, 168, 347-358. (Pubitemid 36920920)
11. Dhatt RK, Gudehithlu KP, Wemlinger TA, Tejwani GA, Neff NH, Hadjiconstantinou M: Preproenkephalin mRNA and methionine-enkephalin content are increased in mouse striatum after treatment with nicotine. J Neurochem, 1995, 64, 1878-1883.
12. Di Chiara G: Role of dopamine in behavioral actions of nicotine related to addiction. Eur J Pharmacol, 2000, 393, 295-314.
13. Fiore MC: Public health service clinical practice guideline: treating tobacco use and dependence. Respir Care, 2000, 45, 1200-1262.
14. Fiserova M, Consolo S, Krsiak M: Chronic morphine induces long-lasting changes in acetylcholine release in rat nucleus accumbens core and shell: an in vivo microdialysis study. Psychopharmacology, 1999, 142, 85-94. (Pubitemid 29196068)
15. Gómez C, Carrasco C, Redolat R: Effects of bupropion, alone or coadministered with nicotine, on social behavior in mice. Addict Biol, 2008, 13, 301-309.
16. Helge TD, Denelsky GY: Pharmacologic aids to smoking cessation. Cleve Clin J Med, 2000, 67, 21-24.
17. Houdi AA, Dasgupta R, Kindy MS: Effect of nicotine use and withdrawal on brain preproenkephalin A mRNA. Brain Res, 1998, 799, 257-263. (Pubitemid 28351255)
18. Houdi AA, Pierzchala K, Marson L, Palkovits M, Van Loon GR: Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides, 1991, 12, 161-166.
19. Itzhak Y, Martin JL: Cocaine-induced conditioned place preference in mice: induction, extinction and reinstatement by related psychostimulants. Neuropsychopharmacology, 2002, 26, 130-134. (Pubitemid 34075285)
20. Johnson SW, North RA: Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci, 1992, 12, 483-488.
21. Joshi D, Singh A, Naidu PS, Kulkarni SK: Protective effect of bupropion on morphine tolerance and dependence in mice. Eur J Pharmacol, 2000, 393, 295-314.
22. Kitamura Y, Yagi T, Kitagawa K, Shinomiya K, Kawasaki H, Asanuma M, Gomita Y: Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats. Naunyn Schmiedebergs Arch Pharmacol, 2010, 382, 151-158.
23. Koob GF, Weiss F, Tiffany ST, Zieglgansberger W, Spanagel R: Animal models of craving: a roundtable discussion. Alcohol Res Health, 1999, 23, 233-236.
24. A receptors in the ventral tegmental area. Nat Neurosci, 2004, 7, 160-169.
25. Liu X, Caggiula AR, Palmatier MI, Donny EC, Sved AF: Cue-induced reinstatement of nicotine-seeking behavior in rats: effect of bupropion, persistence over repeated tests, and its dependence on training dose. Psychopharmacology (Berl), 2008, 196, 365-375. (Pubitemid 351191172)
26. 3H]nicotine binding sites in the rat brain. Neurosci Lett, 1985, 53, 179-184.
27. Malin DH: Nicotine dependence studies with a laboratory model. Pharmacol Biochem Behav, 2001, 70, 551-559.
28. Mansvelder HD, Fagen ZM, Chang B, Mitchum R, McGehee DS: Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area. Biochem Pharmacol, 2007, 74, 1283-1291. (Pubitemid 47417936)
29. Mansvelder HD, Keath JR, McGehee DS: Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron, 2002, 33, 905-919. (Pubitemid 34246356)
30. Mansvelder HD, McGehee DS: Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron, 2000, 27, 349-357.
31. Mathieu AM, Caboche J, Besson MJ: Distribution of preproenkephalin, preprotachykinin A, and preprodynorphin mRNAs in the rat nucleus accumbens: effect of repeated administration of nicotine. Synapse, 1996, 23, 94-106. (Pubitemid 26127244)
32. Mueller D, Perdikaris D, Stewart J: Persistence and drug-induced reinstatement of a morphine-induced conditioned place preference. Behav Brain Res, 2002, 136, 389-397. (Pubitemid 35333253)
33. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC: Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology, 1989, 2, 273-279. (Pubitemid 20025254)
34. O'Brien CP, Childress AR, McLellan AT, Ehrman R: Classical conditioning in drug-dependent humans. Ann NY Acad Sci, 1992, 654, 400-415.
35. Ortmann R: The conditioned place preference paradigm in rats: effect of bupropion. Life Sci, 1985, 37, 2021-2027.
36. Peto R, Chen ZM, Boreham J: Tobacco - the growing epidemic. Nat Med, 1999, 5, 15-17. (Pubitemid 29050987)
37. Picciotto MR, Caldarone BJ, King SL, Zachariou V: Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology, 2000, 22, 451-465.
38. Rauhut AS, Hawrylak M, Mardekian SK: Bupropion differentially alters the aversive, locomotor and rewarding properties of nicotine in CD-1 mice. Pharmacol Biochem Behav, 2008, 90, 598-607.
39. Rauhut AS, Neugebauer N, Dwoskin LP, Bardo MT: Effect of bupropion on nicotine self-administration in rats. Psychopharmacology (Berl), 2003, 169, 1-9. (Pubitemid 37088608)
40. Ribeiro Do Couto B, Aguilar MA, Rodríguez-Arias M, Mińarro J: Long-lasting rewarding effects of morphine induced by drug primings. Brain Res, 2005, 1050, 53-63. (Pubitemid 40931926)
41. 1) receptor activation is a key step for the reactivation of cocaine conditioned place preference by drug priming. Psychopharmacology (Berl), 2004, 175, 154-162.
42. Sinha R: How does stress increase risk of drug abuse and relapse? Psychopharmacology, 2001, 158, 343-359.
43. Slemmer JE, Martin BR, Damaj MI: Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther, 2000, 295, 321-327.
44. Spanagel R, Weiss F: The dopamine hypothesis of reward: past and current status. Trends Neurosci, 1999, 22, 521-527. (Pubitemid 29481853)
45. Tome AR, Izaguirre V, Rosario LM, Cena V, Gonzales-Garcia G: Naloxone inhibits nicotine-induced receptor current and catecholamine secretion in bovine chromaffin cells. Brain Res, 2001, 903, 62-65. (Pubitemid 32904607)
46. Tzschentke TM: Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol, 2007, 12, 227-462.
47. Wang B, Luo F, Zhang WT, Han JS: Stress or drug priming induces reinstatement of extinguished conditioned place preference. Neuroreport, 2000, 11, 2781-2784.
48. Watkins SS, Stinus L, Koob GF, Markou A: Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J Pharmacol Exp Ther, 2000, 292, 1053-1064. (Pubitemid 30136601)
49. Wewers ME, Dhatt RK, Snively TA, Tejwani GA: The effect of chronic administration of nicotine on antinociception, opioid receptor binding and metenkephalin levels in rats. Brain Res, 1999, 822, 107-113. (Pubitemid 29222834)
50. Zaniewska M, Przegaliński E, Filip M: Nicotine dependence - human and animal studies, current pharmacotherapies and future perspectives. Pharmacol Rep, 2009, 61, 957-965
51. Zarrindast MR, Farzin D: Nicotine attenuates naloxone-induced jumping behavior in morphine-dependent mice. Eur J Pharmacol, 1996, 298, 1-6.